Clinical Trial Update: Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating prophylactic traditional Chinese medicine (TCM) to mitigate dermatological adverse effects related to EGFR-TKI therapy in ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Lung Cancer

Drugs mentioned

• Prophylactic TCM

Snippet

Sponsor: China Medical University Hospital | Conditions: Advanced Lung Adenocarcinoma | Phase 3 | Status: COMPLETED